SYRE
Spyre Therapeutics Inc.
93.20$
+3.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 99.4% | 99.9% | 99.9% | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 43.7% | 55.3% | 46.7% | 10.4% | 17.0% | 14.7% | 8.5% | 15.2% | 12.9% | 11.0% | 12.7% | 13.8% | |
| 98.2% | 99.2% | 99.4% | 97.7% | 98.4% | 99.1% | 99.1% | 97.7% | 96.4% | 97.3% | 97.1% | 97.6% | |
| 0.1% | – | – | – | – | – | – | 0.6% | 0.7% | – | 0.6% | – | |
| 218.4% | 46.2% | 68.8% | 14.1% | 22.3% | 14.9% | 15.3% | 15.4% | 9.8% | 8.0% | 12.2% | 6.1% | |
| 21.6% | 9.4% | 8.8% | 5.1% | 13.7% | 8.9% | 12.4% | 15.4% | 9.2% | 7.5% | 11.1% | 5.4% | |
| 0.8% | 0.3% | 0.6% | 0.7% | 1.2% | 0.1% | 0.6% | 0.7% | 1.5% | 1.1% | 0.7% | 0.5% | |
| -118.4% | 53.8% | 31.2% | 85.9% | 77.7% | 85.1% | 84.7% | 84.6% | 90.2% | 92.0% | 87.8% | 93.9% | |
| -338.3% | -223.6% | -165.8% | -194.3% | -217.6% | -159.8% | -178.5% | -195.6% | -211.1% | -145.0% | -156.6% | -105.1% | |
| 2.1% | 6.3% | 7.5% | 10.4% | 12.1% | 7.7% | 10.6% | 11.3% | 12.0% | 9.7% | 10.3% | 7.2% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.